NZS Capital LLC Purchases 5,855 Shares of Repligen Co. (NASDAQ:RGEN)

NZS Capital LLC grew its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 4.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 133,694 shares of the biotechnology company's stock after buying an additional 5,855 shares during the period. NZS Capital LLC owned 0.24% of Repligen worth $19,244,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Susquehanna Fundamental Investments LLC bought a new stake in Repligen in the fourth quarter worth $576,000. Coldstream Capital Management Inc. raised its position in shares of Repligen by 6.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 2,332 shares of the biotechnology company's stock worth $336,000 after purchasing an additional 138 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Repligen by 474.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 159,057 shares of the biotechnology company's stock worth $22,895,000 after purchasing an additional 131,347 shares in the last quarter. Pinebridge Investments L.P. grew its position in Repligen by 42.7% during the 4th quarter. Pinebridge Investments L.P. now owns 18,110 shares of the biotechnology company's stock valued at $2,607,000 after purchasing an additional 5,417 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is owned by company insiders.

Repligen Stock Performance

NASDAQ RGEN traded down $0.79 on Thursday, reaching $137.20. 481,876 shares of the stock were exchanged, compared to its average volume of 718,897. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a one year low of $102.97 and a one year high of $182.52. The firm has a market capitalization of $7.70 billion, a PE ratio of -269.02, a PEG ratio of 4.54 and a beta of 1.27. The company's 50-day simple moving average is $138.77 and its two-hundred day simple moving average is $145.87.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Repligen's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.28 EPS. Analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a report on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target on the stock. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price target on the stock. Finally, Royal Bank of Canada reduced their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $173.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.